US EditionProton Therapy Shows Survival Benefit in Phase III Trial for Patients with Head and Neck Cancers
A multi-institutional U.S. trial led by MD Anderson shows proton therapy improves 5-year survival by 10% and reduces toxicities in advanced oropharyngeal cancer patients.
- On Dec. 11, 2025, researchers at the University of Texas MD Anderson Cancer Center reported a randomized Phase III trial showing 10 percent greater five-year overall survival with proton therapy.
- Proton therapy reduces collateral radiation to normal tissues compared with IMRT, improving treatment tolerance and potentially survival, said Jennifer Maggiore, NAPT.
- Randomizing 440 patients, the trial enrolled 17 proton centers and showed patients with oropharyngeal cancers had lower rates of difficulty swallowing .
- The National Association for Proton Therapy called for immediate access and urged payors and legislators to remove barriers, noting more than 90 percent of initial denials for Medicare Advantage beneficiaries are overturned on appeal.
- Clinicians and researchers note that emerging data across multiple disease sites support clinical and cost-saving evidence, positioning proton therapy as a potential game changer, said Jennifer Maggiore.
56 Articles
56 Articles
New Lancet Phase III Study Shows Proton Therapy Significantly Improves Survival and Reduces Toxicity in Head and Neck Cancers - Marking a Breakthrough in Advanced Cancer Care
Ten percent higher 5-year overall survival rates in patients receiving precise proton therapy vs. traditional radiation therapyPatients had significantly fewer side effects and improved quality of life, including less feeding tube dependence, less dry mouth, better swallowing, improved work productivity,…
Proton therapy shows survival benefit in Phase III trial for patients with head and neck cancers
A study published in The Lancet showed a significant survival benefit for patients with oropharyngeal cancers who were treated with proton therapy (IMPT) compared to those treated with traditional radiation therapy (IMRT).
Proton therapy may help throat cancer patients live longer
A new study has found that people with throat cancer may live longer if they are treated with a newer type of radiation therapy called proton therapy, compared to the standard method used in hospitals today. The study was published in The Lancet and led by doctors from The University of Texas MD Anderson Cancer […] The post Proton therapy may help throat cancer patients live longer appeared first on Knowridge Science Report.
Inova proton therapy shows survival benefit in landmark phase III trial for head and neck cancer patients
FAIRFAX, VA – A new study published today in The Lancet demonstrates a significant survival benefit for patients with oropharyngeal cancers of the head and neck treated with proton therapy compared with traditional radiation therapy (photon therapy). Inova Schar Cancer and The Mather Proton Therapy Center, home to Northern Virginia’s only proton therapy center and one of only 40 in the country, was among a select group of community-based cancer …
An important study published in The Lancet shows that patients with orthofaring cancer treated with proton therapy (IMPT) had a survival rate greater than five years and less severe adverse reactions to traditional radiotherapy (IMRT). Oropharyngic cancer treatment is difficult because tumors appear to be nearly [...]
Coverage Details
Bias Distribution
- 76% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
